MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
-$7,430,261
Unit: Dollar
Positive Cash Flow Breakdown
Issuance of series d preferred s...
Proceeds from 2.5m streeterville...
Stock-based compensation
Others
Negative Cash Flow Breakdown
Capitalized software
Deferred offering costs
Principal repayments on the 2.5m...
Others
Subscribe for Financial Insights
Page 1
Annual
123
Page 1
Cash Flow
2026-04-30
Net loss
-9,141,875
Depreciation
27,791
Amortization of debt discounts and deferred financing costs
495,950
Amortization - right-of-use assets, operating lease
103,559
Impairment of deferred offering costs
748,599
Stock-based compensation
1,312,383
Warrants issued to non-employees
108,335
Accounts receivable
-4,350
Inventory
5,362
Prepaid and other current assets
-237,863
Deferred offering costs
604,736
Capitalized software
715,191
Accounts payable
-334
Accrued liabilities
121,479
Other current liabilities
0
Lease liability, operating lease
-119,518
Net cash used in operating activities
-7,426,707
Purchase of property and equipment
3,554
Acquisition of intellectual property - intangibles
40,898
Net cash used in investing activities
-44,452
Issuance of common stock, net of fees
172,839
Issuance of series d preferred stock and warrants, net of issuance costs
5,549,207
Proceeds from shareholder note, net
0
Proceeds from 2.5m streeterville note, net-Streeterville Note One
0
Proceeds from 2.5m streeterville note, net-Streeterville Note Two
3,000,000
Principal repayments on the 2.5m streeterville note-Streeterville Note One
450,000
Principal repayments of financed insurance premiums
242,171
Net cash provided by investing activities
8,029,875
Net change in cash and cash equivalents during the year
558,716
Cash and cash equivalents, beginning of year
1,098,098
Cash and cash equivalents, end of year
1,656,814
Page 1
Unit: Dollar.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Issuance of series d
preferred stock and...
$5,549,207
Proceeds from 2.5m
streeterville note,...
$3,000,000
Issuance of common stock,
net of fees
$172,839
Net cash provided by
investing activities
$8,029,875
Canceled cashflow
$692,171
Net change in cash
and cash...
$558,716
Canceled cashflow
$7,471,159
Principal repayments on
the 2.5m...
$450,000
Principal repayments of
financed insurance...
$242,171
Stock-based compensation
$1,312,383
Impairment of deferred
offering costs
$748,599
Amortization of debt
discounts and deferred...
$495,950
Prepaid and other
current assets
-$237,863
Accrued liabilities
$121,479
Warrants issued to
non-employees
$108,335
Amortization - right-of-use
assets, operating lease
$103,559
Depreciation
$27,791
Accounts receivable
-$4,350
Net cash used in
operating activities
-$7,426,707
Net cash used in
investing activities
-$44,452
Canceled cashflow
$3,160,309
Net loss
-$9,141,875
Acquisition of intellectual
property - intangibles
$40,898
Purchase of property and
equipment
$3,554
Capitalized software
$715,191
Deferred offering costs
$604,736
Lease liability,
operating lease
-$119,518
Inventory
$5,362
Accounts payable
-$334
Buy us a coffee
HeartSciences Inc. (HSCS)
HeartSciences Inc. (HSCS)